Who owns KALARIS THERAPEUTICS INC COM?
- Ticker: KLRS
- CUSIP Number: 482929106
Tip: Access positions for across all investors
Analyze quarterly positions in Kalaris Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Kalaris Therapeutics stock
Who bought or sold KALARIS THERAPEUTICS INC COM this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Samsara BioCapital | 13M | $109M | 13% | Dec 2025 |
|
| Rtw Investments | 1.3M | $11M | 100% | Dec 2025 |
|
| Paradigm Biocapital Advisors | 700k | $5.9M | 100% | Dec 2025 |
|
| Siren | 436k | $3.7M | 37% | Dec 2025 |
|
| Alyeska Investment Group | 404k | $3.4M | 100% | Dec 2025 |
|
| Ikarian Capital | 360k | $3.0M | 100% | Dec 2025 |
|
| Vanguard Group | 293k | $2.5M | 44% | Dec 2025 |
|
| Woodline Partners | 100k | $844k | -59% | Dec 2025 |
|
| ADAR1 Capital Management | 100k | $844k | 100% | Dec 2025 |
|
| Boothbay Fund Management | 92k | $779k | 100% | Dec 2025 |
|
| Raymond James Financial | 88k | $746k | 100% | Dec 2025 |
|
| Renaissance Technologies | 88k | $741k | -22% | Dec 2025 |
|
| Redmile Group | 83k | $480k | 0% | Sep 2025 |
|
| Geode Capital Management | 83k | $698k | 28% | Dec 2025 |
|
| 683 Capital Management | 81k | $680k | 100% | Dec 2025 |
|
| Marshall Wace | 73k | $615k | 416% | Dec 2025 |
|
| Propel Bio Management | 42k | $355k | 100% | Dec 2025 |
|
| Belpointe Asset Management | 40k | $338k | 0% | Dec 2025 |
|
| Fortis Capital Advisors | 40k | $338k | 0% | Dec 2025 |
|
| BlackRock | 39k | $325k | -5% | Dec 2025 |
|
| Goldman Sachs Group | 34k | $290k | 53% | Dec 2025 |
|
| Jane Street | 33k | $280k | 100% | Dec 2025 |
|
| OMERS Administration Corporation | 30k | $253k | 100% | Dec 2025 |
|
| State Street Corporation | 25k | $215k | 12% | Dec 2025 |
|
| Squarepoint Ops | 25k | $214k | -37% | Dec 2025 |
|
| Millennium Management | 25k | $144k | -54% | Sep 2025 |
|
| Bridgeway Capital Management | 23k | $130k | 100% | Sep 2025 |
|
| Simplify Asset Management | 20k | $169k | 100% | Dec 2025 |
|
| Rbf Capital | 17k | $101k | 0% | Sep 2025 |
|
| Northern Trust | 14k | $115k | 100% | Dec 2025 |
|
| Susquehanna International | 13k | $109k | 100% | Dec 2025 |
|
| Walleye Trading Advisors | 11k | $95k | 100% | Dec 2025 |
|
| XTX Topco | 11k | $92k | 100% | Dec 2025 |
|
| Keel Point | 10k | $86k | 100% | Dec 2025 |
|
| Connor, Clark & Lunn Investment Management | 10k | $86k | 100% | Dec 2025 |
|
| Johnson Financial Group | 10k | $84k | 0% | Dec 2025 |
|
| FMR | 7.8k | $45k | 0% | Sep 2025 |
|
| Barclays | 6.1k | $51k | 100% | Dec 2025 |
|
| Nano Cap New Millennium Growth Fund | 4.0k | $34k | 100% | Dec 2025 |
|
| UBS Group | 2.7k | $23k | -49% | Dec 2025 |
|
| Fortitude Family Office | 114.00 | $962.000400 | 100% | Dec 2025 |
|
| Royal Bank of Canada | 85.00 | $0 | 0% | Sep 2025 |
|
| Bnp Paribas Arbitrage, Snc | 52.00 | $438.999600 | -63% | Dec 2025 |
|
| Jpmorgan Chase & Co | 50.00 | $289.130000 | 100% | Sep 2025 |
|
| Parallel Advisors | 49.00 | $414.001000 | 0% | Dec 2025 |
|
| SBI Securities | 5.00 | $42.000000 | -38% | Dec 2025 |
|
Who sold out of Kalaris Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Tang Capital Management | Sep 2025 | 418k | $2.4M |
| Two Sigma Advisers | Jun 2025 | 20k | $54k |
| Federated Investors | Sep 2025 | 578.00 | $3.3k |
| Strengthening Families & Communities | Sep 2025 | 268.00 | $1.5k |
| Farther Finance Advisors | Sep 2025 | 33.00 | $191.000700 |